LINC 2020 Session: Latest Insights on the Safety and Efficacy of Drug-Coated Devices

LINC 2020 Session: Latest Insights on the Safety and Efficacy of Drug-Coated Devices

Presented Tuesday, January 28, 2020

Moderators: D. Scheinert, W. Gray
Panel: H. Yokoi, A. Holden, M. Brodmann, P. Schneider, T. Zeller, E. Freisinger

Focus on Paclitaxel safety
09:30 – 09:40 The controversy about paclitaxel safety – where do we stand? A summary of concerns, available data, and open questions A. Holden

09:40 – 09:45 First-time data release: In-depth independent safety analysis by Syntactx (CRO) of the Lutonix SFA DCB K. Ouriel

09:45 – 09:50 First-time data release: Paclitaxel exposure and dosage of drug-coated balloons for the treatment of PAD: exploring mortality rates by regions around the globe P. Schneider

09:50 – 09:55 New long-term information on PTX-coated DCB: 5-year results from the AcoArt study W. Guo

09:55 – 10:00 Latest information on long-term efficacy and safety on the Zilver PTX programme
T. Zeller

10:00 – 10:05 Mortality after use of paclitaxel-based devices in peripheral arteries: A real-world safety analysis E. Freisinger

10:05 – 10:12 The presence and the future of drug-coated devices: What to expect in the next 5 years? W. Gray

10:12 – 10:17 Panel discussion